CTOs on the Move

Juventas Therapeutics

www.juventasinc.com

 
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.juventasinc.com
  • 3615 Superior Avenue Suite 4403C
    Cleveland, OH USA 44114
  • Phone: 216.273.4000
  • Fax: 216.359.0099

Executives

Name Title Contact Details

Funding

Juventas Therapeutics raised $14M on 05/13/2015

Similar Companies

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

Avellino Lab

Avellino is a global leader in precision medicine, focused on innovative genetic diagnostics, gene therapies, and genetic data for modern eyecare practices.

Novan Therapeutics

Novan is a clinical-stage drug development company focused on topical delivery of nitric oxide. The company`s proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms. Novan is currently developing innovative, first-in-class therapies for the field of dermatology.

One Tast

One Tast is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioscience

Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.